» Articles » PMID: 34737974

Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area

Overview
Date 2021 Nov 5
PMID 34737974
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The over-prescription of antibiotics is thought to represent a major threat to public health worldwide and is more frequently observed in some low- and middle-income countries. In the Asia-Pacific region, economic development, health care organization and population demographics are very heterogenous. The objective of this survey was to investigate antibiotic use and probiotic co-prescription among adult patients in this area.

Methods: An online survey of physicians from seven countries of the Asia-Pacific region (Australia, Japan, Indonesia, India, China, Singapore and South Korea) was performed in 2018. The questionnaire explored current practices of physicians concerning antibiotics and probiotics and factors related to prescribing decisions.

Results: A total of 387 general practitioners and 350 gastroenterologists completed the questionnaire. Physicians in Australia, Japan and South-Korea were low prescribers of antibiotics (11% to 19% of visits resulted in an antibiotic prescription), while physicians in Indonesia, India, China and Singapore were high prescribers (41% to 61%). A large majority (85%) of physicians agreed that antibiotics disrupted intestinal microbiota. The rates of co-prescription of probiotics varied from 16% in Japan to 39% in Singapore (overall, 27%). Conditions considered by physicians to be prevented by probiotics were mostly antibiotic-associated diarrhea (62%) and colitis (43%).

Conclusions: Rates of probiotic co-prescription remain low in many countries although the negative effects of antibiotics on the gut microbiota and the benefits of co-prescribing probiotics are generally known.

Citing Articles

Unraveling the Microbial Symphony: Impact of Antibiotics and Probiotics on Infant Gut Ecology and Antibiotic Resistance in the First Six Months of Life.

Qi Q, Wang L, Zhu Y, Li S, Gebremedhin M, Wang B Antibiotics (Basel). 2024; 13(7).

PMID: 39061284 PMC: 11274100. DOI: 10.3390/antibiotics13070602.


Interpretable machine learning models for predicting the incidence of antibiotic- associated diarrhea in elderly ICU patients.

Cui Y, Zhou Y, Liu C, Mao Z, Zhou F BMC Geriatr. 2024; 24(1):458.

PMID: 38789951 PMC: 11127392. DOI: 10.1186/s12877-024-05028-8.


Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?.

Waitzberg D, Guarner F, Hojsak I, Ianiro G, Polk D, Sokol H Adv Ther. 2024; 41(3):901-914.

PMID: 38286962 PMC: 10879266. DOI: 10.1007/s12325-024-02783-3.


Awareness Regarding Antimicrobial Resistance and Antibiotic Prescribing Behavior among Physicians: Results from a Nationwide Cross-Sectional Survey in India.

Mittal N, Goel P, Goel K, Sharma R, Nath B, Singh S Antibiotics (Basel). 2023; 12(10).

PMID: 37887197 PMC: 10604884. DOI: 10.3390/antibiotics12101496.


A Real-World Perspective of Co-amoxiclav Prescription Pattern With Probiotics for Pediatric Patients With Respiratory Tract Infections: Results of Quantitative and Qualitative Approach in Indian Outpatient Settings.

Choudhury J, Makkar A, Sharma V, Karamath S, Parmar V, Kumar J P Cureus. 2023; 15(3):e36269.

PMID: 37073213 PMC: 10105827. DOI: 10.7759/cureus.36269.

References
1.
Imperial I, Ibana J . Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect. Front Microbiol. 2016; 7:1983. PMC: 5156686. DOI: 10.3389/fmicb.2016.01983. View

2.
Shah D, Dang M, Hasbun R, Koo H, Jiang Z, DuPont H . Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010; 8(5):555-64. PMC: 3138198. DOI: 10.1586/eri.10.28. View

3.
McFarland L . Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006; 101(4):812-22. DOI: 10.1111/j.1572-0241.2006.00465.x. View

4.
Duan H, Yu L, Tian F, Zhai Q, Fan L, Chen W . Antibiotic-induced gut dysbiosis and barrier disruption and the potential protective strategies. Crit Rev Food Sci Nutr. 2020; 62(6):1427-1452. DOI: 10.1080/10408398.2020.1843396. View

5.
Johnston B, Lytvyn L, Lo C, Allen S, Wang D, Szajewska H . Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants. Infect Control Hosp Epidemiol. 2018; 39(7):771-781. DOI: 10.1017/ice.2018.84. View